CHEMGENEX TO BEGIN CML DRUG TRIAL

A A

Chemgenex will begin international Phase II/III trials of its drug Ceflatonin, which is used to treat patients with chronic myeloid leukemia (CML) who cannot be treated with existing treatments.

The company is fast-tracking the trial, to be conducted on patients at 15 clinics in countries including the U.S., Germany and France. It hopes to lodge the treatment for registration with the FDA by mid-2007.